Treating bladder tumor cells using fibronectin attachment protein as a target
AssigneePurdue Research Foundation
InventorsRuben Claudio Aguilar, Timothy Ratliff, David Thompson, Scott Crist
Life of this patent
Estimating the term…
Abstract
Composition and methods are disclosed for utilizing micro-aggregation of FAP-containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum-free conditions such as the ones found in the lumen of the bladder.
Claims20
A method of enhancing targeted uptake of therapeutic or diagnostic agents by a patient's cells, said method comprising the steps of:
- providing a multivalent complex comprising at least one carrier and a plurality of fibronectin attachment proteins or functional equivalents thereof attached to the carrier such that each fibronectin attachment protein or functional equivalent thereof is positioned within submicrons of at least one other fibronectin attachment protein or functional equivalent to form a cluster and wherein said complex is linked to a therapeutic or diagnostic agent;
- and
- administering said complex to said patient;
- wherein upon contact between receptors of a patient cell and the fibronectin attachment proteins or functional equivalents thereof of the complex, the cluster further comprises the receptors of the patient cell.
A method of enhancing the targeted uptake of therapeutic or diagnostic agents by a patient's bladder cells, said method comprising the steps of
- providing a complex that comprises:
- a plurality of recombinant fusion peptides, each peptide comprising a fibronectin attachment protein and a non-native peptide tag;
- a plurality of ligands bound to said recombinant fusion peptides;
- a nanoparticle or nano-carrier wherein said ligands are linked to said nanoparticle or nano-carrier surface and spaced less than 150 nm apart from each other such that each fibronectin attachment protein is positioned within submicrons of at least one other fibronectin attachment protein of the complex to form a cluster;
- and
- a therapeutic or diagnostic agent linked to said ligand or peptide;
- and
- contacting said cells with said complex.
A method for enhancing selective uptake of diagnostic or therapeutic agents by a patient's bladder tumor cells comprising the steps of:
- providing a stable multivalent complex of fibronectin attachment proteins, wherein the fibronectin attachment protein complex comprises at least one carrier, a plurality of fibronectin attachment proteins attached to the carrier, and a plurality of ligands that bind to fibronectin attachment protein and position at least two fibronectin attachment proteins within submicrons of each other to form a cluster, and wherein said complex is linked to a therapeutic or diagnostic agent;
- and
- contacting said bladder tumor cells with said complex;
- wherein upon contact between receptors of a bladder tumor cell and the fibronectin attachment proteins of the complex, the cluster further comprises the receptors of the bladder tumor cell.
Dependencies are inferred from the claim text.